Member Info for Steadydanny

Patent!

Tenatry its not just US! CHECK OUT THE PAYENT!

Celtic and Barnowl. Hi. Effectively we have a patent so advanced that I might consider has a touch of flt3 to it that we are way ahead of the curve re treatments. I could warble on so as to up the submarine patent as I do for which i apologise.
The government yesterday mentioned in plain sight the vaccines are effectively ineffective. Treatments are required.
Let's all look up what thymine or previously known as tyrosine is going to be relevant due to its depletion due to .....
It's a discussion board...

Desperate jason?

Jashar. This is why. My post 12th November

And this USPTO
25 March 2021
U.S. patent application number 17/108266 was filed with the patent office on 2021-03-25 for pharmaceutical compounds. This patent application is currently assigned to Sareum Limited. The applicant listed for this patent is Sareum Limited. Invention is credited to John Charles READER
Then this
Equivalents

[0509] The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitation on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.
When the penny drops.
READ IT ATLEAST 3 TIMES. SLOWLY .
The dates I mentioned. The timelines. The re negotiation. The cover. The noteable 737 mention increase in Sareum RNSs. The 1801 able to progress by ourselves. The 1802 similar rapid progress due to similarity and 'same initial pathways'.
Remember a submerged submarine patent when partially released...any future competitve approved products have a very very hard time to prove they did not 'borrow' the patent. We receive payments and royalties.
Just look at what is occurring with 737 since then. And the rest of it.
Jashar..you are welcome.

Maybe tyk2 might assist?

Toxicology results are imo imminent. The way they are incentivised are down to the release of the submarine patent . I'm probably on my own why cytokine storms will be an issue but so far I am content and daily being more content with my opinion. It will be about people requiring treatments post vaccination.

Zylo. Hi. I'm pretty sure the toxicology results are in hand and have no reason for delay in response beyond 2021.

Jashar you are a coward.

Jashar you are very selective with RNS reports and fail to administer the whole response
Try this
Dr Tim Mitchell, CEO of Sareum, commented:

"The past year has seen Sareum advance the preclinical development of our proprietary dual TYK2/JAK1 inhibitor programmes, with the goal of completing preclinical development of SDC-1801 and filing for clinical trials approval by the end of 2021. We are particularly pleased to have raised substantial additional funding during the period, which will be deployed to advance these programmes into clinical development and build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets."
All I can say is you are biased. Anyhow once again what's your opinion on cytokine storms and cytotoxicity and the depletion of tyrosine?

Your comment jashar
Celtic here the problem and what spooked some people. I know the toxicology take time and no one suggests rushing. When you notify a market of cta several times and then delay- what we’re they doing during the time then or we’re those initial notifications premature. Any way they look to have it under way now so I won’t dwell on the past.
Literally who is rushing the results, they have always been destined to be revealed before year end.
I take it you work overtime for PH.

So what's your take on 1802 jashar?

Jashar I will ask this every time you post.

Yes Bobbler. Its imo about cytokine storms and cytotoxicity due to a reduction in natural immunity for some reason.

Bobbler I assume you are relating to the ones that have been rushed out by big pharma?

Literally just said above and beyond vaccines we are working on anti viral treatments.

If you were a HNWI and undertook a subscription of shares at 8.25p at a cost of £1million after 2 prior HNWIs invested £900k, £1.47m and £1m at increasing prices due to rising sp, and accepted by the BODS that they were granted at a slightly less than trading price at point of purchase (check the RNSs) ...at which point would anyone deem the sp to be less than 8.25p with a 1 for 1.25 warrant opportunity if sp reaches greater than 10.25p after 5 days?
Does anyone really think our board (albeit v quiet) but NED makes a cursory purchase, because only they can....think they would have accepted such a subscription which would imo cement the boards opinion of what the ipr is worth and potentially worth?

Hi Krone. And yes the first HNWI was 900k 1st June and next 1.47m 15 June.
And then we know the rest. The media said we were at a financial loss in their reports.
Shame they didn't contend the point that we have put funds towards ongoing trials and consultations of which the BOD were working on.

Hi Zylo re your Agile comment is this re 25th Oct RNS

We are now considering how we might make use of the UK government's AGILE clinical trial platform, or other equivalent programmes, to providing funding and support for Phase 1 trials with SDC-1801 for Covid-19 applications and potentially fast-track its development. The timing and design of these clinical trials will be determined following consultations with experts in the field.

It is evident that that there is still a clear need for new therapies to treat severe respiratory inflammation arising from viral infections such as Covid-19 despite the success of the UK vaccination programme and the availability of vaccines around the world. With TYK2 acknowledged as a key therapeutic target for severe Covid-19 in an article published in December 2020 in the leading scientific journal, Nature*, we believe that SDC-1801 could have a role to play in this area in the future and we look forward to updating shareholders on further progress.

Anyone know what alternative programmes are? Is that sub licensing? Royalties etc?
Odd fact but the founder of Nature journal is buried about 100m from where I'm sat.
Anyhow back to the point ...the tweets....the shake...the ipr patent updates...737 in use with AZ via Sierra...submarine patent....and the pill isn't as effective as hoped ...so maybe a capsule that when a submarine patent breaks ground any pharma that uses the outlined findings will have a very very hard time to prove any future released 'treatments' are their own!
Bish bash bosh.

I don't know about you Afham but I have butterflies in my tummy. The good kind. I just got this feeling inside that something is happening and it's good.
Just my opinion but I feel excitedly nervous.